Organogenesis
(NASDAQ) ORGO
Organogenesis Financials at a Glance
Market Cap
$308.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$513.57M
Net Income (TTM)
-$284.00K
EPS (TTM)
-$0.16
P/E Ratio
-15.09
Dividend
$0.00
Beta (Volatility)
1.58 (High)
Dividend
$0.00
Beta (Volatility)
1.58 (High)
Price
$2.40
Volume
1,340,506.411
Open
$2.47
Price
$2.40
Volume
1,340,506.411
Open
$2.47
Previous Close
$2.40
Daily Range
$2.36 - $2.47
52-Week Range
$2.04 - $7.08
Estimated Earnings Date
Aug 6, 2026
Dividend
$0.00
Beta (Volatility)
1.58 (High)
Price
$2.40
Volume
1,340,506.411
Open
$2.47
Previous Close
$2.40
Daily Range
$2.36 - $2.47
52-Week Range
$2.04 - $7.08
Estimated Earnings Date
Aug 6, 2026
ORGO News
ORGO Sales Drop 23%
ORGO: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Organogenesis
Industry
Biotechnology
Sector
Health CareEmployees
854
CEO
Gary S. Gillheeney, Sr., MBA
Website
www.organogenesis.comHeadquarters
Canton, MA 02021, US
ORGO Financials
Key Financial Metrics (TTM)
Gross Margin
70.41%
Operating Margin
2.14%
Net Income Margin
-0.06%
Return on Equity
-0.07%
Return on Capital
9.86%
Return on Assets
-0.05%
Earnings Yield
-6.63%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$308.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
128.68M
Volume
1.34M
Avg. Volume
1.13M
Financials (TTM)
Gross Profit
$361.62M
Operating Income
$11.02M
EBITDA
$37.31M
Operating Cash Flow
$30.75M
Capital Expenditure
-$13.67M
Free Cash Flow
$17.08M
Cash & ST Invst.
$92.10M
Total Debt
$70.86M
Organogenesis Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$37.23M
-57.1%
Gross Profit
-$914.00K
-101.5%
Gross Margin
-2.46%
N/A
Market Cap
$308.82MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$355.37K
N/A
Employees
869
N/A
Net Income
-$56.16M
-198.0%
EBITDA
-$56.10M
-187.7%
Quarterly Fundamentals
Total Cash
$92.10M
-16.2%
Total Debt
$70.86M
+66.2%
Accounts Receivable
$116.91M
+13.2%
Inventory
$28.43M
-3.1%
Long Term Debt
$61.14M
+83.2%
Short Term Debt
$9.72M
+5.0%
Return on Assets
-0.05%
N/A
Return on Invested Capital
2.48%
N/A
Free Cash Flow
$17.98M
+176.3%
Operating Cash Flow
$21.13M
+206.0%